Hangzhou Tigermed Consulting Co akcijos akcijų analizė | Akcijų kaina | Naujienos | 300347.SZ | CNE100001KV8 |

Data	Hangzhou Tigermed Consulting Co Akcijų kaina
2024-09-06	48,73 undefined
2024-09-05	50,46 undefined
2024-09-04	49,90 undefined
2024-09-03	49,81 undefined
2024-09-02	48,44 undefined
2024-08-30	50,87 undefined
2024-08-29	51,18 undefined
2024-08-28	48,68 undefined
2024-08-27	47,58 undefined
2024-08-26	48,54 undefined
2024-08-23	47,61 undefined
2024-08-22	47,76 undefined
2024-08-21	48,59 undefined
2024-08-20	50,00 undefined
2024-08-19	53,18 undefined
2024-08-16	53,58 undefined
2024-08-15	52,60 undefined
2024-08-14	52,20 undefined
2024-08-13	54,23 undefined
2024-08-12	53,42 undefined

Data	Hangzhou Tigermed Consulting Co Pajamos	Hangzhou Tigermed Consulting Co EBIT	Hangzhou Tigermed Consulting Co Pelnas
2026e	11,38 mlrd. undefined	3,17 mlrd. undefined	1,89 mlrd. undefined
2025e	9,71 mlrd. undefined	2,73 mlrd. undefined	1,63 mlrd. undefined
2024e	8,35 mlrd. undefined	2,34 mlrd. undefined	1,37 mlrd. undefined
2023	7,38 mlrd. undefined	1,71 mlrd. undefined	2,02 mlrd. undefined
2022	7,09 mlrd. undefined	1,78 mlrd. undefined	2,01 mlrd. undefined
2021	5,21 mlrd. undefined	1,43 mlrd. undefined	2,87 mlrd. undefined
2020	3,19 mlrd. undefined	956,70 mln. undefined	1,75 mlrd. undefined
2019	2,80 mlrd. undefined	802,80 mln. undefined	841,60 mln. undefined
2018	2,30 mlrd. undefined	628,00 mln. undefined	472,20 mln. undefined
2017	1,69 mlrd. undefined	423,60 mln. undefined	301,00 mln. undefined
2016	1,17 mlrd. undefined	167,50 mln. undefined	140,70 mln. undefined
2015	957,00 mln. undefined	210,90 mln. undefined	156,30 mln. undefined
2014	624,60 mln. undefined	153,80 mln. undefined	125,50 mln. undefined
2013	336,50 mln. undefined	89,00 mln. undefined	94,10 mln. undefined
2012	254,30 mln. undefined	66,70 mln. undefined	67,70 mln. undefined
2011	193,30 mln. undefined	54,00 mln. undefined	47,80 mln. undefined
2010	122,80 mln. undefined	34,50 mln. undefined	31,70 mln. undefined
2009	62,80 mln. undefined	7,10 mln. undefined	7,80 mln. undefined

	Pajamos	EBIT	Pelnas
2009	62,80 mln. CNY	7,10 mln. CNY	7,80 mln. CNY
2010	122,80 mln. CNY	34,50 mln. CNY	31,70 mln. CNY
2011	193,30 mln. CNY	54,00 mln. CNY	47,80 mln. CNY
2012	254,30 mln. CNY	66,70 mln. CNY	67,70 mln. CNY
2013	336,50 mln. CNY	89,00 mln. CNY	94,10 mln. CNY
2014	624,60 mln. CNY	153,80 mln. CNY	125,50 mln. CNY
2015	957,00 mln. CNY	210,90 mln. CNY	156,30 mln. CNY
2016	1,17 mlrd. CNY	167,50 mln. CNY	140,70 mln. CNY
2017	1,69 mlrd. CNY	423,60 mln. CNY	301,00 mln. CNY
2018	2,30 mlrd. CNY	628,00 mln. CNY	472,20 mln. CNY
2019	2,80 mlrd. CNY	802,80 mln. CNY	841,60 mln. CNY
2020	3,19 mlrd. CNY	956,70 mln. CNY	1,75 mlrd. CNY
2021	5,21 mlrd. CNY	1,43 mlrd. CNY	2,87 mlrd. CNY
2022	7,09 mlrd. CNY	1,78 mlrd. CNY	2,01 mlrd. CNY
2023	7,38 mlrd. CNY	1,71 mlrd. CNY	2,02 mlrd. CNY
2024e	8,35 mlrd. CNY	2,34 mlrd. CNY	1,37 mlrd. CNY
2025e	9,71 mlrd. CNY	2,73 mlrd. CNY	1,63 mlrd. CNY
2026e	11,38 mlrd. CNY	3,17 mlrd. CNY	1,89 mlrd. CNY

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0,06	0,12	0,19	0,25	0,34	0,62	0,96	1,17	1,69	2,30	2,80	3,19	5,21	7,09	7,38	8,35	9,71	11,38
-	96,77	58,20	31,61	32,28	85,71	53,37	22,68	43,70	36,34	21,87	13,88	63,31	35,91	4,22	13,04	16,28	17,27
33,87	45,90	45,08	46,06	44,94	47,28	44,10	37,99	42,92	43,09	46,45	47,43	43,54	39,63	38,53	-	-	-
0,02	0,06	0,09	0,12	0,15	0,30	0,42	0,45	0,72	0,99	1,30	1,51	2,27	2,81	2,85	0	0	0
0,01	0,03	0,05	0,07	0,09	0,15	0,21	0,17	0,42	0,63	0,80	0,96	1,43	1,78	1,71	2,34	2,73	3,17
11,29	27,87	27,98	25,98	26,49	24,52	21,94	14,22	25,07	27,30	28,61	29,95	27,41	25,11	23,19	28,00	28,17	27,86
0,01	0,03	0,05	0,07	0,09	0,13	0,16	0,14	0,30	0,47	0,84	1,75	2,87	2,01	2,02	1,37	1,63	1,89
-	342,86	51,61	42,55	40,30	32,98	24,80	−10,26	115,00	56,81	78,18	107,97	64,32	−30,20	0,90	−32,11	18,27	16,43
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
405,20	473,00	480,00	533,60	640,80	638,10	650,00	703,30	750,30	750,30	744,80	799,00	870,96	864,89	865,32	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022	2023

0,02	0,04	0,09	0,56	0,53	0,45	0,24	0,54	0,61	0,70	2,11	9,99	8,57	8,41	7,81	7,48
0,02	0,02	0,05	0,09	0,13	0,30	0,38	0,45	0,63	0,78	1,16	1,32	2,10	2,09	3,03	3,63
1,00	2,00	5,00	8,00	10,00	10,00	42,00	72,00	67,00	58,00	64,00	119,00	75,85	82,78	98,29	109,23
0	0	0	0	0	0	0	0	0	1,00	1,00	5,00	6,10	6,10	22,20	23,40
1,00	21,00	8,00	4,00	8,00	21,00	23,00	36,00	34,00	64,00	41,00	220,00	94,79	260,73	153,97	103,30
0,04	0,09	0,14	0,66	0,68	0,79	0,69	1,09	1,35	1,60	3,37	11,65	10,85	10,85	11,11	11,34
0,02	0,02	0,02	0,05	0,08	0,15	0,19	0,20	0,20	0,26	0,43	0,68	1,12	1,14	1,34	1,49
0	0	0	0	0,02	0,05	0,19	0,46	0,88	1,33	2,36	5,37	9,50	9,50	11,80	13,22
0	0	0	0	0	0	0	0	0	0	0	0	75,85	0	0	0
0	0	8,00	9,00	10,00	19,00	14,00	13,00	17,00	28,00	96,00	142,00	250,64	250,64	338,12	371,13
0,01	0,01	0,01	0,01	0,02	0,34	0,47	0,60	1,05	1,03	1,16	1,45	1,78	1,78	2,49	2,76
0	1,00	3,00	2,00	2,00	15,00	50,00	17,00	87,00	36,00	122,00	223,00	219,00	219,00	380,99	492,47
0,03	0,03	0,04	0,07	0,13	0,57	0,92	1,29	2,24	2,68	4,16	7,86	12,95	12,89	16,34	18,34
0,07	0,12	0,19	0,73	0,81	1,36	1,61	2,39	3,58	4,28	7,53	19,51	23,80	23,74	27,45	29,68

30,00	40,00	40,00	53,00	107,00	215,00	433,00	475,00	500,00	500,00	750,00	872,00	872,44	872,44	872,42	872,42
0,01	0,03	0,03	0,49	0,44	0,38	0,18	0,67	1,27	1,32	1,71	12,00	11,89	11,89	11,85	11,71
0,00	0,03	0,08	0,14	0,19	0,28	0,39	0,48	0,72	1,10	1,94	3,48	6,09	6,09	7,66	9,21
0	0	0	0	0	−0,01	−0,00	0,00	−0,00	−0,00	0,03	−0,09	2,33	−0,16	0,06	0,09
0	0	0	0	0	0	0	0	0	0	0	0	0	0	8,88	8,83
0,04	0,09	0,14	0,69	0,74	0,86	1,00	1,63	2,49	2,92	4,42	16,25	21,17	18,69	20,45	21,90
0	0	2,00	12,00	14,00	17,00	10,00	15,00	24,00	44,00	75,00	101,00	147,87	125,75	157,96	249,31
0	1,00	3,00	6,00	8,00	22,00	27,00	43,00	55,00	89,00	156,00	183,00	350,68	350,68	403,50	461,53
0,02	0,02	0,03	0,02	0,03	0,08	0,18	0,20	0,32	0,41	0,63	0,78	1,35	1,33	1,15	0,91
0	0	0	0	0	0,27	0,26	0,18	0,27	0,64	0,89	0,02	0,49	0,53	1,88	1,99
0	0	0	0	0	0	0	0	63,00	29,00	33,00	52,00	74,52	74,52	137,32	519,57
0,02	0,02	0,04	0,04	0,05	0,39	0,47	0,44	0,73	1,21	1,79	1,14	2,41	2,41	3,73	4,14
0	0	0	0	0	7,00	24,00	33,00	32,00	19,00	154,00	279,00	406,84	406,84	733,62	857,33
0	0	0	0	0	4,00	9,00	17,00	13,00	14,00	46,00	132,00	201,54	201,54	214,39	213,98
0	1,00	3,00	0	0	43,00	40,00	64,00	4,00	4,00	20,00	97,00	−3 351,33	114,88	87,90	17,13
0	0,00	0,00	0	0	0,05	0,07	0,11	0,05	0,04	0,22	0,51	−2,74	0,72	1,04	1,09
0,02	0,02	0,04	0,04	0,05	0,44	0,54	0,55	0,78	1,25	2,01	1,65	−0,33	3,14	4,77	5,23
0,07	0,12	0,18	0,73	0,80	1,30	1,55	2,18	3,27	4,16	6,43	17,90	20,84	21,83	25,22	27,12

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	2,87	0	0
0	0	0	0	0	0	0	0	0	0	0	0	188,00	0	329,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	−7,00
3,00	−10,00	−16,00	−93,00	−104,00	−238,00	−462,00	−552,00	−671,00	−921,00	−1 157,00	−1 314,00	−98,00	−1 734,00	−2 420,00
0	0	0	0	0	0	0	0	0	0	0	0	−1 548,00	0	−285,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
−3,00	−4,00	−15,00	−17,00	−26,00	−41,00	−59,00	−71,00	−127,00	−140,00	−234,00	−241,00	−321,00	−321,00	−594,00
0,02	0,03	0,04	0,02	0,08	0,04	0,19	0,19	0,32	0,52	0,53	1,00	1,42	1,42	1,36
−13,00	−8,00	−16,00	−21,00	−37,00	−38,00	−87,00	−61,00	−46,00	−91,00	−102,00	−156,00	−368,00	−368,00	−448,00
−34,00	−20,00	4,00	−22,00	−139,00	−219,00	−413,00	−530,00	−846,00	−366,00	−638,00	−2 367,00	−2 782,00	−2 782,00	−2 789,00
−20,00	−12,00	20,00	−1,00	−102,00	−181,00	−326,00	−468,00	−800,00	−274,00	−535,00	−2 210,00	−2 414,00	−2 414,00	−2 340,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0,23	−0,01	−0,05	0,08	0,34	0,18	−0,90	0,40	0,49	1,61
0	0	0	0	0	0	0	0	0	0	0	0	−227,00	0	−87,00
0	0,02	0	0,48	−0,04	0,12	0,01	0,49	0,70	0,01	1,43	9,34	−0,16	−0,16	0,81
0	0,02	0	0,48	0,00	−0,06	0,07	0,59	0,69	−0,20	1,52	10,51	−0,05	−0,37	−0,31
0	0	0	0	−43,00	−46,00	−46,00	−59,00	−62,00	−126,00	−266,00	−271,00	−284,00	−284,00	−491,00
0,01	0,07	0,11	0,60	0,10	0,27	0,51	0,98	1,28	1,76	3,26	10,48	1,95	1,90	3,78
8,00	18,30	22,50	−6,70	39,70	5,60	98,60	130,20	269,00	430,50	424,70	842,20	1 055,18	1 055,18	908,90
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Hangzhou Tigermed Consulting Co Bruto marža	Hangzhou Tigermed Consulting Co Pelnas-martža	Hangzhou Tigermed Consulting Co EBIT marža	Hangzhou Tigermed Consulting Co Pelnas-martža
2026e	38,53 %	27,86 %	16,62 %
2025e	38,53 %	28,17 %	16,74 %
2024e	38,53 %	28,00 %	16,47 %
2023	38,53 %	23,20 %	27,42 %
2022	39,64 %	25,12 %	28,32 %
2021	43,55 %	27,42 %	55,13 %
2020	47,43 %	29,97 %	54,81 %
2019	46,48 %	28,64 %	30,02 %
2018	43,10 %	27,30 %	20,52 %
2017	42,94 %	25,11 %	17,84 %
2016	38,03 %	14,26 %	11,98 %
2015	44,12 %	22,04 %	16,33 %
2014	47,33 %	24,62 %	20,09 %
2013	45,05 %	26,45 %	27,96 %
2012	46,24 %	26,23 %	26,62 %
2011	45,11 %	27,94 %	24,73 %
2010	45,60 %	28,09 %	25,81 %
2009	34,39 %	11,31 %	12,42 %

	Bruto marža	EBIT marža	Pelnas-martža
2009	34,39 %	11,31 %	12,42 %
2010	45,60 %	28,09 %	25,81 %
2011	45,11 %	27,94 %	24,73 %
2012	46,24 %	26,23 %	26,62 %
2013	45,05 %	26,45 %	27,96 %
2014	47,33 %	24,62 %	20,09 %
2015	44,12 %	22,04 %	16,33 %
2016	38,03 %	14,26 %	11,98 %
2017	42,94 %	25,11 %	17,84 %
2018	43,10 %	27,30 %	20,52 %
2019	46,48 %	28,64 %	30,02 %
2020	47,43 %	29,97 %	54,81 %
2021	43,55 %	27,42 %	55,13 %
2022	39,64 %	25,12 %	28,32 %
2023	38,53 %	23,20 %	27,42 %
2024e	38,53 %	28,00 %	16,47 %
2025e	38,53 %	28,17 %	16,74 %
2026e	38,53 %	27,86 %	16,62 %

Data	Hangzhou Tigermed Consulting Co Pardavimai vienai akcijai	Hangzhou Tigermed Consulting Co EBIT vienai akcijai	Hangzhou Tigermed Consulting Co Pelnas vienai akcijai
2026e	20,08 undefined	0 undefined	3,34 undefined
2025e	17,13 undefined	0 undefined	2,87 undefined
2024e	14,73 undefined	0 undefined	2,43 undefined
2023	8,53 undefined	1,98 undefined	2,34 undefined
2022	8,19 undefined	2,06 undefined	2,32 undefined
2021	5,99 undefined	1,64 undefined	3,30 undefined
2020	4,00 undefined	1,20 undefined	2,19 undefined
2019	3,76 undefined	1,08 undefined	1,13 undefined
2018	3,07 undefined	0,84 undefined	0,63 undefined
2017	2,25 undefined	0,56 undefined	0,40 undefined
2016	1,67 undefined	0,24 undefined	0,20 undefined
2015	1,47 undefined	0,32 undefined	0,24 undefined
2014	0,98 undefined	0,24 undefined	0,20 undefined
2013	0,53 undefined	0,14 undefined	0,15 undefined
2012	0,48 undefined	0,13 undefined	0,13 undefined
2011	0,40 undefined	0,11 undefined	0,10 undefined
2010	0,26 undefined	0,07 undefined	0,07 undefined
2009	0,15 undefined	0,02 undefined	0,02 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2009	0,15 CNY	0,02 CNY	0,02 CNY
2010	0,26 CNY	0,07 CNY	0,07 CNY
2011	0,40 CNY	0,11 CNY	0,10 CNY
2012	0,48 CNY	0,13 CNY	0,13 CNY
2013	0,53 CNY	0,14 CNY	0,15 CNY
2014	0,98 CNY	0,24 CNY	0,20 CNY
2015	1,47 CNY	0,32 CNY	0,24 CNY
2016	1,67 CNY	0,24 CNY	0,20 CNY
2017	2,25 CNY	0,56 CNY	0,40 CNY
2018	3,07 CNY	0,84 CNY	0,63 CNY
2019	3,76 CNY	1,08 CNY	1,13 CNY
2020	4,00 CNY	1,20 CNY	2,19 CNY
2021	5,99 CNY	1,64 CNY	3,30 CNY
2022	8,19 CNY	2,06 CNY	2,32 CNY
2023	8,53 CNY	1,98 CNY	2,34 CNY
2024e	14,73 CNY	0 CNY	2,43 CNY
2025e	17,13 CNY	0 CNY	2,87 CNY
2026e	20,08 CNY	0 CNY	3,34 CNY

	Akcijų skaičius
2009	405,20 mln. Aktien
2010	473,00 mln. Aktien
2011	480,00 mln. Aktien
2012	533,60 mln. Aktien
2013	640,80 mln. Aktien
2014	638,10 mln. Aktien
2015	650,00 mln. Aktien
2016	703,30 mln. Aktien
2017	750,30 mln. Aktien
2018	750,30 mln. Aktien
2019	744,80 mln. Aktien
2020	799,00 mln. Aktien
2021	870,96 mln. Aktien
2022	864,89 mln. Aktien
2023	865,32 mln. Aktien
2024e	865,32 mln. Aktien
2025e	865,32 mln. Aktien
2026e	865,32 mln. Aktien

Data	Hangzhou Tigermed Consulting Co Dividendas
2026e	0,60 undefined
2025e	0,60 undefined
2024e	0,60 undefined
2023	0,55 undefined
2022	0,50 undefined
2021	0,30 undefined
2020	0,28 undefined
2019	0,23 undefined
2018	0,13 undefined
2017	0,07 undefined
2016	0,07 undefined
2015	0,07 undefined
2014	0,07 undefined
2013	0,07 undefined

	Dividendas	Dividenda (įvertinimas)
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0 CNY	0 CNY
2012	0 CNY	0 CNY
2013	0,07 CNY	0 CNY
2014	0,07 CNY	0 CNY
2015	0,07 CNY	0 CNY
2016	0,07 CNY	0 CNY
2017	0,07 CNY	0 CNY
2018	0,13 CNY	0 CNY
2019	0,23 CNY	0 CNY
2020	0,28 CNY	0 CNY
2021	0,30 CNY	0 CNY
2022	0,50 CNY	0 CNY
2023	0,55 CNY	0 CNY
2024e	0 CNY	0,60 CNY
2025e	0 CNY	0,60 CNY
2026e	0 CNY	0,60 CNY

Data	Hangzhou Tigermed Consulting Co Išmokėjimo santykis
2026e	15,49 %
2025e	17,01 %
2024e	15,03 %
2023	14,45 %
2022	21,55 %
2021	9,09 %
2020	12,69 %
2019	20,65 %
2018	21,16 %
2017	16,67 %
2016	33,33 %
2015	27,78 %
2014	33,33 %
2013	44,44 %
2012	14,45 %
2011	14,45 %
2010	14,45 %
2009	14,45 %

	Išmokėjimo santykis
2009	14,45 %
2010	14,45 %
2011	14,45 %
2012	14,45 %
2013	44,44 %
2014	33,33 %
2015	27,78 %
2016	33,33 %
2017	16,67 %
2018	21,16 %
2019	20,65 %
2020	12,69 %
2021	9,09 %
2022	21,55 %
2023	14,45 %
2024e	15,03 %
2025e	17,01 %
2026e	15,49 %

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2024-06-30	0,50	0,30 (−40,00 %)	2024 Q2
2024-03-31	0,54	0,27 (−49,66 %)	2024 Q1
2023-12-31	0,46	0,17 (−63,33 %)	2023 Q4
2023-09-30	0,75	0,57 (−24,40 %)	2023 Q3
2023-06-30	0,66	0,95 (44,11 %)	2023 Q2
2023-03-31	0,62	0,66 (6,43 %)	2023 Q1
2022-12-31	0,63	0,46 (−26,46 %)	2022 Q4
2022-09-30	0,67	0,48 (−28,39 %)	2022 Q3
2022-06-30	0,65	0,78 (20,23 %)	2022 Q2
2022-03-31	0,63	0,60 (−5,05 %)	2022 Q1
2021-12-31	0,45	1,27 (181,28 %)	2021 Q4
2021-09-30	0,41	0,61 (48,94 %)	2021 Q3
2021-06-30	0,55	0,92 (68,68 %)	2021 Q2
2021-03-31	0,39	0,52 (32,01 %)	2021 Q1
2020-12-31	0,18	0,49 (166,89 %)	2020 Q4
2020-09-30	0,35	0,39 (11,62 %)	2020 Q3
2020-06-30	0,28	0,99 (257,45 %)	2020 Q2
2020-03-31	0,28	0,34 (21,02 %)	2020 Q1
2019-12-31	0,33	0,43 (27,78 %)	2019 Q4
2019-09-30	0,22	0,23 (6,48 %)	2019 Q3
2019-06-30	0,26	0,28 (5,50 %)	2019 Q2
2019-03-31	0,19	0,19 (−0,31 %)	2019 Q1
2018-12-31	0,18	0,21 (14,65 %)	2018 Q4
2018-09-30	0,16	0,13 (−19,47 %)	2018 Q3
2018-06-30	0,16	0,16 (3,81 %)	2018 Q2
2018-03-31	0,12	0,13 (5,47 %)	2018 Q1
2017-12-31	0,14	0,13 (−5,23 %)	2017 Q4

%	Pavadinimas	Akcijos	Pokytis	Data
9,11634 %	Cao (Xiaochun)	51 661 774	0	2023-12-31
5,36834 %	Zhong Ou Asset Management Co., Ltd.	30 422 105	−14 368 400	2023-12-31
4,61012 %	Bank of Communications Schroder Fund Management Co., Ltd.	26 125 259	−15 100	2023-12-31
31,27604 %	Ye (Xiaoping)	177 239 541	0	2023-12-31
3,84346 %	E Fund Management Co. Ltd.	21 780 670	821 200	2023-12-31
2,49134 %	Hwabao WP Fund Management Co., Ltd.	14 118 309	−2 081 100	2023-12-31
2,18981 %	Temasek Fullerton Alpha Pte. Ltd.	12 409 532	−6 681 467	2023-12-31
2,00655 %	INVESCO Great Wall Fund Management Co. Ltd.	11 371 023	3 382 548	2023-12-31
1,88429 %	Shi (Xiao Li)	10 678 175	0	2023-12-31
1,80344 %	Zhuan (Yin)	10 220 000	0	2023-12-31
1,75792 %	China Merchants Fund Management Co. Ltd.	9 962 011	−487 879	2023-12-31
1,33521 %	HuaAn Fund Management Co., Ltd.	7 566 557	47 000	2023-12-31
1,32195 %	Federated Hermes International	7 491 394	1 511 094	2024-02-29
1,09251 %	GF Fund Management Co., Ltd.	6 191 174	1 535 900	2023-12-31
0,98719 %	China Universal Asset Management Co., Ltd.	5 594 332	−322 011	2023-12-31
0,97587 %	abrdn Asia Limited	5 530 194	−331 900	2024-02-29
0,96202 %	Tianhong Asset Management Co., Ltd.	5 451 728	4 200	2023-12-31
0,91425 %	Schroder Investment Management (Hong Kong) Ltd.	5 181 026	0	2023-12-31
0,90022 %	UBS Asset Management (Hong Kong) Limited	5 101 477	0	2023-12-31
0,78643 %	Harvest Fund Management Co., Ltd.	4 456 672	0	2024-02-29
0,77939 %	Yinhua Fund Management Co., Ltd.	4 416 734	63 200	2023-12-31
0,72978 %	Huatai-PineBridge Fund Management Co., Ltd.	4 135 631	2 002 693	2023-12-31
0,68922 %	JPMorgan Asset Management (Asia Pacific) Limited	3 905 777	0	2024-03-31
0,68614 %	Morgan Stanley Investment Management (China) Company Limited.	3 888 305	−754 877	2023-12-31
0,63106 %	J.P. Morgan Asset Management (Singapore) Limited	3 576 156	−584 100	2022-08-31
0,53495 %	China Southern Asset Management Co. Ltd.	3 031 505	−270 570	2023-12-31
0,50668 %	Fullgoal Fund Management Co., Ltd.	2 871 334	−209 400	2023-12-31
0,50647 %	China Asset Management Co., Ltd.	2 870 130	504 467	2023-12-31
0,39034 %	Galaxy Asset Management Co., Ltd.	2 212 059	283 000	2023-12-31
0,36558 %	The Vanguard Group, Inc.	2 071 736	−81 400	2024-03-31
0,36034 %	Ping An Fund Management Company Limited	2 042 000	0	2023-12-31
0,34430 %	Guotai Asset Management Co., Ltd.	1 951 149	−11 200	2023-12-31
0,26582 %	APG Asset Management N.V.	1 506 364	−471	2023-09-30
0,21161 %	Norges Bank Investment Management (NBIM)	1 199 167	−624 672	2023-12-31
0,20610 %	China Fund Management Co., Ltd.	1 167 940	17 900	2023-12-31
0,20138 %	Allianz Global Investors Singapore Ltd.	1 141 206	−6 136 795	2023-01-31
0,18247 %	Grandeur Peak Global Advisors, LLC	1 034 068	−68 100	2024-01-31
0,18075 %	ICBC Credit Suisse Asset Management Co. Ltd.	1 024 300	−400	2023-12-31
0,15434 %	UBS Asset Management (UK) Ltd.	874 648	500	2024-03-31
0,15173 %	Rongtong Fund Management Co., Ltd.	859 866	2 200	2023-12-31
0,13808 %	Wanjia Asset Management Co., Ltd.	782 480	695 680	2023-06-30
0,12716 %	Great Wall Fund Management Co., Ltd.	720 594	−1 209 441	2023-06-30
0,12439 %	Bosera Asset Management Co., Ltd.	704 910	154 400	2023-12-31
0,12200 %	Invesco Advisers, Inc.	691 390	0	2022-10-31
0,09682 %	UBS Asset Management (Switzerland)	548 674	0	2024-02-29
0,09481 %	Fidelity Management & Research (Hong Kong) Limited	537 305	−43 400	2024-02-29
0,09302 %	BlackRock Institutional Trust Company, N.A.	527 141	25 900	2024-03-31
0,08447 %	PengYang Asset Management Co., Ltd	478 693	−30 800	2023-06-30
0,07977 %	Harvest Global Investments Limited	452 032	0	2024-03-31
0,07799 %	Dacheng Fund Management Co., Ltd.	441 990	200	2023-12-31
0,07778 %	Cinda Fund Management Co., Ltd.	440 762	440 762	2023-12-31
0,07669 %	BlackRock Advisors (UK) Limited	434 621	16 100	2024-03-31
0,06990 %	Penghua Fund Management Co., Ltd.	396 146	190 467	2023-06-30
0,06750 %	Principal Global Investors (Hong Kong) Limited	382 500	382 500	2022-12-31
0,06225 %	China Asset Management (Hong Kong) Limited	352 789	26 200	2024-03-31
0,05598 %	Wasatch Global Investors Inc	317 238	−26 700	2023-12-31
0,05329 %	Orient Securities Asset Management Company Limited	302 000	−10 417	2023-06-30
0,04830 %	California State Teachers Retirement System	273 731	−120 155	2023-06-30
0,04791 %	DWS Investments UK Limited	271 510	−647	2024-03-31
0,04668 %	State Street Global Advisors (US)	264 539	−5 000	2024-03-31
0,04659 %	Truvalue Asset Management Co., Ltd.	264 000	−757 671	2023-06-30
0,04282 %	Amundi Asset Management, SAS	242 672	55 600	2024-03-31
0,04147 %	Huashang Fund Management Co., Ltd.	235 000	41 300	2023-12-31
0,04134 %	Capital Investment Trust Corporation	234 244	234 244	2023-12-31
0,04067 %	Guotai Junan Securities Assets Management Co., Ltd.	230 500	133 600	2023-06-30
0,03241 %	Mellon Investments Corporation	183 667	−5 800	2024-03-31
0,02993 %	Lion Fund Management Co., Ltd.	169 594	96 000	2023-12-31
0,02984 %	Matthews International Capital Management, L.L.C.	169 076	0	2024-02-29
0,02924 %	SEB Asset Management (Denmark)	165 678	−168 003	2024-02-29
0,02501 %	Mirae Asset Global Investments Co., Ltd.	141 758	138	2024-01-31
0,02476 %	Taikang Asset Management Co., Ltd.	140 307	−4 300	2023-06-30
0,02431 %	Degroof Petercam Asset Management	137 756	−12 109	2023-12-31
0,02396 %	Tibet Eastmoney Fund Management Co., Ltd.	135 800	−10 700	2023-12-31
0,02337 %	Western Leadbank Fund Management Co., Ltd.	132 459	68 000	2023-06-30
0,02328 %	BlackRock (Singapore) Limited	131 927	29 022	2024-03-31
0,02322 %	China Life AMP Asset Management Co., Ltd	131 609	4 300	2023-12-31
0,02169 %	CITIC Prudential Fund Management Co., Ltd.	122 900	2 000	2023-06-30
0,02144 %	Beixin Ruifeng Fund Management Co., Ltd.	121 500	23 500	2023-12-31
0,01953 %	JT Asset Management Co., Ltd.	110 700	−16 600	2023-06-30
0,01922 %	JPMorgan Asset Management (China) Company Limited.	108 900	8 000	2023-06-30
0,01740 %	Taiping Fund Management Co., Ltd.	98 600	98 600	2023-06-30
0,01680 %	Everbright PGIM Fund Management Co., Ltd.	95 225	−13 400	2023-12-31
0,01606 %	CCB Principal Asset Management Co., Ltd.	91 008	−1 300	2023-12-31
0,01590 %	JPMorgan Asset Management U.K. Limited	90 102	1 000	2024-03-31
0,01551 %	BlackRock Investment Management, LLC	87 900	−2 200	2023-12-31
0,01540 %	SWS MU Fund Management Co., Ltd.	87 291	−8 400	2023-06-30
0,01509 %	Maxwealth Fund Management Co., Ltd.	85 532	20 100	2023-06-30
0,01498 %	Founder Fubon Fund Management Co., Ltd.	84 900	−600	2023-12-31
0,01493 %	Xingyin Fund Management Co., Ltd.	84 600	−5 900	2023-06-30
0,01469 %	Geode Capital Management, L.L.C.	83 257	6 500	2024-02-29
0,01246 %	Amundi Japan Ltd.	70 600	8 200	2024-03-31
0,01242 %	Nikko Asset Management Asia Limited	70 394	−249 892	2023-11-30
0,01234 %	Union Investment Privatfonds GmbH	69 941	−419 964	2023-06-30
0,01220 %	Ninety One North America, Inc.	69 156	0	2023-12-31
0,01163 %	State Street Global Advisors (UK) Ltd.	65 883	0	2024-03-31
0,01154 %	CPIC Fund Management Co., Ltd.	65 398	−2 900	2023-12-31
0,01142 %	Charles Schwab Investment Management, Inc.	64 700	0	2024-03-31
0,00990 %	Xinjiang Qianhai Alliance Asset Management Co., Ltd.	56 100	−60 400	2023-06-30
0,00963 %	Purekind Fund Management Co., Ltd.	54 600	−70 400	2023-06-30
0,00960 %	CSOP Asset Management Limited	54 400	0	2024-03-31

What values and corporate philosophy does Hangzhou Tigermed Consulting Co represent?

Hangzhou Tigermed Consulting Co Ltd represents values of trust, innovation, and excellence in the field of clinical research and drug development. As a leading contract research organization, Tigermed is committed to providing high-quality services and solutions to pharmaceutical companies globally. With a strong focus on integrity and professionalism, the company aims to assist clients in achieving their clinical development goals efficiently. Moreover, Tigermed values collaboration, aiming to foster meaningful partnerships with its clients and professionals in the healthcare industry. Through cutting-edge technology and a customer-centric approach, Hangzhou Tigermed Consulting Co Ltd strives to be a reliable and strategic partner in advancing healthcare outcomes.

In which countries and regions is Hangzhou Tigermed Consulting Co primarily present?

Hangzhou Tigermed Consulting Co Ltd is primarily present in China, as it is a Chinese company. However, it also has a significant presence in other countries and regions. With its global expansion strategy, Hangzhou Tigermed Consulting Co Ltd has established branches and offices in numerous locations worldwide. These include the United States, Japan, South Korea, Europe, Australia, and Southeast Asia. This widespread presence allows Hangzhou Tigermed Consulting Co Ltd to offer its comprehensive range of pharmaceutical and clinical research services to clients internationally.

What significant milestones has the company Hangzhou Tigermed Consulting Co achieved?

Hangzhou Tigermed Consulting Co Ltd has achieved significant milestones in its history. As a leading contract research organization (CRO), the company has successfully established a global presence and expanded its service offerings. It has demonstrated its expertise in clinical research, regulatory affairs, and data management, serving clients across various therapeutic areas. Tigermed Consulting has also formed strategic partnerships with renowned pharmaceutical companies, positioning itself as a trusted partner in drug development and clinical trials. With its commitment to innovation and quality, Hangzhou Tigermed Consulting Co Ltd continues to make substantial advancements in the field of healthcare and contribute to improved patient outcomes.

What is the history and background of the company Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co Ltd is a leading contract research organization (CRO) based in China. Founded in 2004, the company has rapidly grown to become one of the largest independent CROs in the country. Tigermed specializes in providing comprehensive clinical research and development services to pharmaceutical and biotech companies globally. With a strong focus on clinical trial management, regulatory affairs, and data management, Tigermed has established a solid reputation for delivering high-quality solutions to its clients. The company's commitment to excellence and extensive experience in the industry has enabled it to forge strong partnerships and contribute significantly to the advancement of healthcare research.

Who are the main competitors of Hangzhou Tigermed Consulting Co in the market?

Some of the main competitors of Hangzhou Tigermed Consulting Co Ltd in the market include PPD Inc., ICON plc, QuintilesIMS, PAREXEL International Corporation, and Wuxi AppTec.

In which industries is Hangzhou Tigermed Consulting Co primarily active?

Hangzhou Tigermed Consulting Co Ltd is primarily active in the pharmaceutical and biotech industries.

What is the business model of Hangzhou Tigermed Consulting Co?

The business model of Hangzhou Tigermed Consulting Co Ltd revolves around providing comprehensive and integrated clinical research services to support the development and marketing of pharmaceutical, biotechnological, and medical device products. As a leading Contract Research Organization (CRO) in China, Tigermed offers a wide range of services including project planning, clinical trial management, regulatory affairs, data management, statistical analysis, and quality assurance. By leveraging their expertise, experience, and strategic partnerships, Hangzhou Tigermed Consulting Co Ltd caters to the growing needs of domestic and international clients in the healthcare industry.

Koks yra Hangzhou Tigermed Consulting Co 2024 KGV?

Hangzhou Tigermed Consulting Co KGV yra 30,68.

Koks Hangzhou Tigermed Consulting Co 2024 KUV?

Hangzhou Tigermed Consulting Co KUV yra 5,05.

Koks yra Hangzhou Tigermed Consulting Co AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Hangzhou Tigermed Consulting Co yra 8/10.

Koks yra Hangzhou Tigermed Consulting Co 2024 pajamų dydis?

tikėtina Hangzhou Tigermed Consulting Co pardavimai yra 8,35 mlrd. CNY.

Kokia yra Hangzhou Tigermed Consulting Co 2024 pelnas?

tikėtina Hangzhou Tigermed Consulting Co pelnas yra 1,37 mlrd. CNY.

Ką daro Hangzhou Tigermed Consulting Co?

The Hangzhou Tigermed Consulting Co Ltd is a leading company in the field of clinical research, offering a wide range of services to its customers. The company was founded in 2004 and has its headquarters in Hangzhou, China. With offices in various cities in China, Europe, and the USA, the company now has over 800 employees worldwide. The business model of Tigermed Consulting is to support companies in developing and bringing new products to market. To this end, the company offers a wide range of services that span the entire product lifecycle. The company provides customers with support in the planning, execution, and evaluation of clinical studies, following applicable regulations and guidelines. The company specializes in clinical studies, regulatory affairs, medical devices, biostatistics, and medical writing services. Tigermed Consulting offers unique services to its customers, providing comprehensive solutions for their clinical studies, regulatory matters, and medical products. The company has experienced significant growth in recent years by offering a broad range of customizable services tailored to the specific needs of its customers. Overall, the business model of Tigermed Consulting aims to help its customers stay competitive and successfully bring their products to market. In a world driven by new technologies and innovations, it is important to leverage the expertise of companies like Tigermed Consulting to operate a successful and profitable business.

Kokia yra Hangzhou Tigermed Consulting Co dividendė?

Hangzhou Tigermed Consulting Co moka dividendą 0,50 CNY, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Hangzhou Tigermed Consulting Co moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Hangzhou Tigermed Consulting Co arba įmonė dividendų nemoka.

Kas yra Hangzhou Tigermed Consulting Co ISIN?

Hangzhou Tigermed Consulting Co ISIN yra CNE100001KV8.

Kas yra Hangzhou Tigermed Consulting Co Tickeris?

Hangzhou Tigermed Consulting Co akcijų simbolis yra 300347.SZ.

Kiek dividendų moka Hangzhou Tigermed Consulting Co?

Per paskutinius 12 mėnesių Hangzhou Tigermed Consulting Co išmokėjo dividendą, kurios dydis siekė 0,55 CNY . Tai atitinka maždaug 1,13 % dividendų grąžą. Artimiausiems 12 mėnesiams Hangzhou Tigermed Consulting Co tikėtina išmokės dividendus, kurie sudarys 0,60 CNY.

Kokia yra Hangzhou Tigermed Consulting Co dividendų grąža?

Hangzhou Tigermed Consulting Co šiuo metu yra 1,13 % dydžio dividendų grąža.

Kada Hangzhou Tigermed Consulting Co moka dividendus?

Hangzhou Tigermed Consulting Co moka dividendus kas ketvirtį. Jie išmokami liepa, birželis, rugpjūtis, rugpjūtis mėnesiais.

Kokia saugi yra Hangzhou Tigermed Consulting Co dividendų išmokėjimas?

Hangzhou Tigermed Consulting Co per paskutiniuosius 14 metus kiekvienais metais mokėjo dividendus.

Kokia yra Hangzhou Tigermed Consulting Co dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0,60 CNY. Tai atitinka 1,22 % dividendų grąžos procentą.

Kokiame sektoriuje yra Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Hangzhou Tigermed Consulting Co dividendą nuo 2024-07-12, kurio dydis yra 0,568 CNY, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-07-12.

Kada Hangzhou Tigermed Consulting Co paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-07-12.

Kokia buvo Hangzhou Tigermed Consulting Co dividendų suma 2023 metais?

2023 metais Hangzhou Tigermed Consulting Co išmokėjo 0,5 CNY dividendų.

Kokia valiuta Hangzhou Tigermed Consulting Co moka dividendus?

Hangzhou Tigermed Consulting Co dividendai yra mokami CNY.

Tiesioginiai išleidimai	110,04
Netiesioginės emisijos iš įsigytos energijos	9 810,26
Tiesioginiai išmetimai iš vertybių grandinės	—
CO₂ emisijos	9 920,3
CO₂ mažinimo strategija	✅
Anglies energija	❌
Atomkraft	❌
Bandymai su gyvūnais	✅
Pelz & Leder	—
Pesticidai	—
Palmių aliejus	—
Tabakas	❌
Genetinė inžinerija	❌
Klimato koncepcija	—
Tvarioji miškininkystė	—
Perdirbimo nuostatai	❌
Aplinkai draugiška pakuotė	❌
Pavojingosios medžiagos	❌
Degalų sąnaudos ir efektyvumas	✅
Vandens suvartojimas ir efektyvumas	✅

Moterų dalis tarp darbuotojų	81,355
Moterų dalis valdyme	—
Azijietiškų darbuotojų dalis	—
Akcijų dalis Azijos valdyme	—
Hispanų/lotynų kilmės darbuotojų dalis	—
Hispanų/latino kilmės vadybos dalis	—
Akcijų turimų tamsios odos darbuotojų procentas	—
Juodaodžių valdymo dalis	—
Baltųjų darbuotojų dalis	—
Baltųjų valdymo dalis	—
Suaugusiųjų turinys	❌
Alkoholis	❌
Ginkluotė	—
Šaunamieji ginklai	❌
Azartiniai lošimai	❌
Karinių sutarčių	❌
Žmogaus teisių koncepcija	✅
Privatumo politika	—
Darbo ir sveikatos apsauga	✅
Katalikiškas	✅

Tvarumo ataskaita	✅
Akcijų turėtojų įtraukimas	✅
Atsiliepimo taisyklės	❌
Kartelio teisė	❌

Hangzhou Tigermed Consulting Co Akcijų kodas	Hangzhou Tigermed Consulting Co FIGI
300347:CH	BBG002PKXG01
300347:CS	BBG002QKZ361
300347:C2	BBG00F13DR59

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodas300347.SZ

ISINCNE100001KV8

Hangzhou Tigermed Consulting Co akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Hangzhou Tigermed Consulting Co Akcijų istorija

Hangzhou Tigermed Consulting Co akcijų apyvarta, EBIT, pelnas CNE100001KV8 ·

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Hangzhou Tigermed Consulting Co Pajamų, pelno ir EBIT istorija.

Hangzhou Tigermed Consulting Co Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Hangzhou Tigermed Consulting Co Akcijos Maržos CNE100001KV8 ·

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Hangzhou Tigermed Consulting Co Maržų istorija

Hangzhou Tigermed Consulting Co akcijos apyvarta, EBIT, pelnas vienai akcijai CNE100001KV8 ·

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Hangzhou Tigermed Consulting Co Pardavimų, pelno ir EBIT istorija vienai akcijai

Hangzhou Tigermed Consulting Co akcija ir akcijų analizė

Hangzhou Tigermed Consulting Co vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Hangzhou Tigermed Consulting Co įvertinimas pagal istorinį P/E, EBIT ir P/S

Hangzhou Tigermed Consulting Co akcijų skaičius CNE100001KV8 ·

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Hangzhou Tigermed Consulting Co Akcijų padalijimai

Hangzhou Tigermed Consulting Co akcijos dividendas CNE100001KV8 ·

Dividendas

Dividendų apžvalga

Interpretacija ir naudojimas

Investavimo strategija

Hangzhou Tigermed Consulting Co Dividendų istorija

Hangzhou Tigermed Consulting Co akcijų išmokėjimo koeficientas CNE100001KV8 ·

Dividendų mokėjimo rodiklis

Kas yra metinis dividendų mokėjimo rodiklis?

Kaip interpretuoti duomenis

Duomenų naudojimas investavimui

Hangzhou Tigermed Consulting Co Dividendų išmokėjimo istorija

Hangzhou Tigermed Consulting Co Pelno prognozės

Padaryk geriausias savo gyvenimo investicijas
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Akcijų kodas
300347.SZ

ISIN
CNE100001KV8